MDL | - |
---|---|
Molecular Weight | 308.34 |
Molecular Formula | C16H16N6O |
SMILES | O=C1N(CC2=CC=CC=C2)CC(NC3=C4N=CNC4=NC=N3)C1 |
(Rac)-Benpyrine, a racemate of Benpyrine, is a potent and orally active TNF-α inhibitor. (Rac)-Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research [1] .
(Rac)-Benpyrine (Compound 001; 5-10 μM; 24 hours) treatment inhibits the expression level of TNF-α downstream pathway protein NF-κB in the nucleus in RAW264.7 macrophages [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
(Rac)-Benpyrine (Compound 001; 25-50 mg/kg; oral gavage; daily; for 3 weeks; Kunming mice) treatment obviously reduces the inflammatory cytokines IFN-γ, IL-1β and IL-6 in the blood serum, and the anti-inflammatory factor IL-10 is obviously increased, the foot swelling degree of the arthritis part is also obviously slowed down, and the weight index increase caused by the arthritis also has no obvious reduction [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Kunming mice (7-8 weeks) treated with bovine type II collagen and a CFA complete adjuvant [1] |
Dosage: | 25 mg/kg, 50 mg/kg |
Administration: | Oral gavage; daily; for 3 weeks |
Result: | The inflammatory cytokines IFN-γ, IL-1β and IL-6 in the blood serum were obviously reduced, and the anti-inflammatory factor IL-10 was obviously increased. |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
DMSO : 12.5 mg/mL ( 40.54 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.2432 mL | 16.2159 mL | 32.4317 mL |
5 mM | 0.6486 mL | 3.2432 mL | 6.4863 mL |
10 mM | 0.3243 mL | 1.6216 mL | 3.2432 mL |